Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCO371 in Hypoparathyroidism
NCT04209179Phase 1Terminated
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of PCO-371 in hypoparathyroidism (4 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Treatment-emergent adverse events at 13 weeks, Selected adverse events at 13 weeks and 2 more. Started Jul 2020; status: terminated.
02
Drugs
PCO-371
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on NCT04209179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04209179.